The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACLARIS THERAPEUTICS INC | COM | 00461U105 | 8,646 | 1,336,275 | SH | SOLE | 1,336,275 | 0 | 0 | ||
| BCLS ACQUISITION CORP | COM CL A | G0904B105 | 2,785 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| C4 THERAPEUTICS INC | COM STK | 12529R107 | 15,939 | 481,094 | SH | SOLE | 481,094 | 0 | 0 | ||
| COGENT BIOSCIENCES INC | COM | 19240Q201 | 8,535 | 760,025 | SH | SOLE | 760,025 | 0 | 0 | ||
| CELLDEX THERAPEUTICS INC NEW | COM NEW | 15117B202 | 6,245 | 356,431 | SH | SOLE | 356,431 | 0 | 0 | ||
| CONSTELLATION PHARMCETICLS I | COM | 210373106 | 12,203 | 423,708 | SH | SOLE | 423,708 | 0 | 0 | ||
| CYCLACEL PHARMACEUTICALS INC | COM | 23254L603 | 2,067 | 264,690 | SH | SOLE | 264,690 | 0 | 0 | ||
| CYMABAY THERAPEUTICS INC | COM | 23257D103 | 8,530 | 1,486,107 | SH | SOLE | 1,486,107 | 0 | 0 | ||
| FIVE PRIME THERAPEUTICS INC | COM | 33830X104 | 9,049 | 532,000 | SH | SOLE | 532,000 | 0 | 0 | ||
| GENOCEA BIOSCIENCES INC | COM NEW | 372427401 | 4,273 | 1,765,901 | SH | SOLE | 1,765,901 | 0 | 0 | ||
| IVERIC BIO INC | COM | 46583P102 | 8,805 | 1,274,261 | SH | SOLE | 1,274,261 | 0 | 0 | ||
| IMMUNOVANT INC | COM | 45258J102 | 3,870 | 83,782 | SH | SOLE | 83,782 | 0 | 0 | ||
| INVENTIVA SA | ADS | 46124U107 | 3,350 | 231,000 | SH | SOLE | 231,000 | 0 | 0 | ||
| KRONOS BIO INC | COM | 50107A104 | 8,926 | 298,839 | SH | SOLE | 298,839 | 0 | 0 | ||
| KURA ONCOLOGY INC | COM | 50127T109 | 4,360 | 133,503 | SH | SOLE | 133,503 | 0 | 0 | ||
| LIFESCI ACQUISITION II CORP | COM | 53229E103 | 1,067 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| MEREO BIOPHARMA GROUP PLC | ADS | 589492107 | 6,638 | 1,854,278 | SH | SOLE | 1,854,278 | 0 | 0 | ||
| MERSANA THERAPEUTICS INC | COM | 59045L106 | 4,226 | 158,827 | SH | SOLE | 158,827 | 0 | 0 | ||
| MILLENDO THERAPEUTICS INC | COM | 60040X103 | 1,980 | 925,000 | SH | SOLE | 925,000 | 0 | 0 | ||
| PMV PHARMACEUTICALS INC | COM | 69353Y103 | 7,689 | 125,000 | SH | SOLE | 125,000 | 0 | 0 | ||
| PROTAGONIST THERAPEUTICS INC | COM | 74366E102 | 7,006 | 347,500 | SH | SOLE | 347,500 | 0 | 0 | ||
| RELMADA THERAPEUTICS INC | COM | 75955J402 | 5,727 | 178,565 | SH | SOLE | 178,565 | 0 | 0 | ||
| SILVERBACK THERAPEUTICS INC | COM | 82835W108 | 4,502 | 97,143 | SH | SOLE | 97,143 | 0 | 0 | ||
| SURFACE ONCOLOGY INC | COM | 86877M209 | 4,322 | 467,796 | SH | SOLE | 467,796 | 0 | 0 | ||
| SYNDAX PHARMACEUTICALS INC | COM | 87164F105 | 7,346 | 330,315 | SH | SOLE | 330,315 | 0 | 0 | ||
| TRILLIUM THERAPEUTICS INC | COM NEW | 89620X506 | 12,546 | 852,871 | SH | SOLE | 852,871 | 0 | 0 | ||
| VISTAGEN THERAPEUTICS INC | COM NEW | 92840H202 | 6,111 | 3,150,000 | SH | SOLE | 3,150,000 | 0 | 0 | ||
| XENON PHARMACEUTICALS INC | COM | 98420N105 | 7,188 | 467,368 | SH | SOLE | 467,368 | 0 | 0 | ||